Published • loading... • Updated
Fractyl Health’s Revita Hits Key Weight-Maintenance Goal in REMAIN-1 Study
Summary by thecerbatgem.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Fractyl Health’s Revita Hits Key Weight-Maintenance Goal in REMAIN-1 Study
Fractyl Health (NASDAQ:GUTS) reported six-month top-line results from its ongoing pivotal REMAIN-1 study evaluating its investigational Revita procedure for maintaining weight loss after patients discontinue GLP-1 obesity medicines. The randomized, double-blind, sham-controlled study enrolled adults with obesity who had not previously received GLP-1 treatment. Participants first received tirzepatide during a run-in period, losing an average […]
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
